Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic characterization of Klebsiella pneumoniae carbapenemase -producing Klebsiella pneumoniae isolates with different susceptibility to ceftazidime/avibactam in patients with blood-stream infections.
Badalucco Ciotta F, Saluzzo F, Pescò A, Di Marco F, Carletti S, Ripa M, Mancini N, Cirillo DM, Castagna A, Oltolini C. Badalucco Ciotta F, et al. Among authors: ripa m. Clin Microbiol Infect. 2023 Dec;29(12):1610-1612. doi: 10.1016/j.cmi.2023.08.024. Epub 2023 Aug 31. Clin Microbiol Infect. 2023. PMID: 37659691 No abstract available.
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.
Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Nozza S, et al. Among authors: ripa m. J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23. J Antimicrob Chemother. 2014. PMID: 24458511 No abstract available.
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, Ottou S, De Battista D, Pogliaghi M, Di Pietro M, Malnati M, Ripa M, Bonora S, Lazzarin A; VEMAN Study Group. Nozza S, et al. Among authors: ripa m. Clin Microbiol Infect. 2015 May;21(5):510.e1-9. doi: 10.1016/j.cmi.2014.12.006. Epub 2014 Dec 11. Clin Microbiol Infect. 2015. PMID: 25656621 Free article. Clinical Trial.
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.
Ripa M, Pogliaghi M, Chiappetta S, Galli L, Pensieroso S, Cavarelli M, Scarlatti G, De Biasi S, Cossarizza A, De Battista D, Malnati M, Lazzarin A, Nozza S, Tambussi G. Ripa M, et al. Clin Microbiol Infect. 2015 Sep;21(9):876.e1-4. doi: 10.1016/j.cmi.2015.05.007. Epub 2015 May 14. Clin Microbiol Infect. 2015. PMID: 25980351 Free article. Clinical Trial.
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: ripa m. Medicine (Baltimore). 2016 May;95(22):e3780. doi: 10.1097/MD.0000000000003780. Medicine (Baltimore). 2016. PMID: 27258510 Free PMC article.
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Gianotti N, Poli A, Nozza S, Galli L, Galizzi N, Ripa M, Merli M, Carbone A, Spagnuolo V, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: ripa m. BMC Infect Dis. 2017 Nov 16;17(1):723. doi: 10.1186/s12879-017-2831-9. BMC Infect Dis. 2017. PMID: 29145807 Free PMC article.
152 results